This white paper examines the landscape of new drug development and clinical trial activity in heart failure, which affects 5.8 Americans and 23 million people globally. In the past five years, just one new/novel drug has been registered with a regulatory authority for approval, and three other compounds with previous approvals in other indications such as hypertension and angina were also registered for heart failure to see where the future of treatment could lead us.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: